SHMT2 Promotes Gastric Cancer Development through Regulation of HIF1α/VEGF/STAT3 Signaling
International Journal of Molecular Sciences · 12.04.2023 · 24 (8) · 7150
DOI: 10.3390/ijms24087150 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.04.2023. Verfasst von Weida Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. Hauptthemen laut MEDLINE: Glycine Hydroxymethyltransferase, Stomach Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Financial support from the CAMS Innovation Fund for Medical Sciences (CIFMS), CAMS Innovation Fund for Medical Sciences (CIFMS).
Abstract (Originalsprache)
The metabolic enzymes involved in one-carbon metabolism are closely associated with tumor progression and could be potential targets for cancer therapy. Recent studies showed that serine hydroxymethyltransferase 2 (SHMT2), a crucial enzyme in the one-carbon metabolic pathway, plays a key role in tumor proliferation and development. However, the precise role and function of SHMT2 in gastric cancer (GC) remain poorly understood. In this study, we presented evidence that SHMT2 was necessary for hypoxia-inducible factor-1α (HIF1α) stability and contributed to GC cells’ hypoxic adaptation. The analysis of datasets retrieved from The Cancer Genome Atlas and the experimentation with human cell lines revealed a marked increase in SHMT2 expression in GC. The SHMT2 knockdown in MGC803, SGC7901, and HGC27 cell lines inhibited cell proliferation, colony formation, invasion, and migration. Notably, SHMT2 depletion disrupted redox homeostasis and caused glycolytic function loss in GC cells under hypoxic circumstances. Mechanistically, we discovered SHMT2 modulated HIF1α stability, which acted as a master regulator of hypoxia-inducible genes under hypoxic conditions. This, in turn, regulated the downstream VEGF and STAT3 pathways. The in vivo xenograft experiments showed that SHMT2 knockdown markedly reduced GC growth. Our results elucidate the novel function of SHMT2 in stabilizing HIF1α under hypoxic conditions, thus providing a potential therapeutic strategy for GC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing 100050, China.
ORCID-Profile: Sen Zhang
Förderung
- Financial support from the CAMS Innovation Fund for Medical Sciences (CIFMS)
- CAMS Innovation Fund for Medical Sciences (CIFMS)
Zitieren
APA
Wang, W., Wang, M., Du, T., Hou, Z., You, S., Zhang, S., Ji, M., Xue, N., & Chen, X. (2023). SHMT2 Promotes Gastric Cancer Development through Regulation of HIF1α/VEGF/STAT3 Signaling. International Journal of Molecular Sciences, 24(8), 7150. https://doi.org/10.3390/ijms24087150
Vancouver
Wang W, Wang M, Du T, Hou Z, You S, Zhang S, et al. SHMT2 Promotes Gastric Cancer Development through Regulation of HIF1α/VEGF/STAT3 Signaling. International Journal of Molecular Sciences. 2023;24(8):7150. doi:10.3390/ijms24087150
BibTeX
@article{Wang2023,
author = {Wang, Weida and Wang, Mingjin and Du, Tingting and Hou, Zhenyan and You, Shen and Zhang, Sen and Ji, Ming and Xue, Nina and Chen, Xiaoguang},
title = {SHMT2 Promotes Gastric Cancer Development through Regulation of HIF1α/VEGF/STAT3 Signaling},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {8},
pages = {7150},
doi = {10.3390/ijms24087150}
}
EUVIMED